| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroblastoma | 17 | 2025 | 550 | 4.110 |
Why?
|
| Liver Neoplasms | 21 | 2024 | 1417 | 2.720 |
Why?
|
| Immunotherapy, Adoptive | 14 | 2025 | 894 | 2.470 |
Why?
|
| Hepatoblastoma | 13 | 2024 | 184 | 2.420 |
Why?
|
| Natural Killer T-Cells | 7 | 2025 | 84 | 2.210 |
Why?
|
| Glypicans | 4 | 2024 | 41 | 2.090 |
Why?
|
| Interleukin-15 | 5 | 2025 | 96 | 1.950 |
Why?
|
| Carcinoma, Hepatocellular | 9 | 2024 | 1007 | 1.640 |
Why?
|
| Receptors, Antigen, T-Cell | 7 | 2025 | 503 | 1.410 |
Why?
|
| T-Lymphocytes | 9 | 2025 | 1812 | 1.260 |
Why?
|
| Bone Neoplasms | 2 | 2023 | 447 | 1.100 |
Why?
|
| Gangliosides | 5 | 2025 | 73 | 1.030 |
Why?
|
| Synthetic Biology | 1 | 2025 | 15 | 0.930 |
Why?
|
| Receptors, Antigen | 3 | 2016 | 34 | 0.900 |
Why?
|
| Neoplasms | 6 | 2025 | 3038 | 0.890 |
Why?
|
| Genetic Engineering | 1 | 2025 | 164 | 0.860 |
Why?
|
| Immunotherapy | 4 | 2017 | 752 | 0.770 |
Why?
|
| Osteosarcoma | 1 | 2023 | 264 | 0.700 |
Why?
|
| CD28 Antigens | 2 | 2016 | 81 | 0.610 |
Why?
|
| Interleukins | 1 | 2020 | 130 | 0.610 |
Why?
|
| DNA | 1 | 2025 | 1682 | 0.610 |
Why?
|
| Personal Satisfaction | 1 | 2018 | 106 | 0.570 |
Why?
|
| Child | 28 | 2025 | 25889 | 0.540 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2016 | 26 | 0.520 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 137 | 0.500 |
Why?
|
| Periodicals as Topic | 1 | 2018 | 201 | 0.490 |
Why?
|
| Osteopetrosis | 1 | 2015 | 13 | 0.490 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 128 | 0.490 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 563 | 0.490 |
Why?
|
| Lymphoma, B-Cell | 2 | 2016 | 149 | 0.480 |
Why?
|
| Femoral Fractures | 1 | 2015 | 34 | 0.480 |
Why?
|
| Diphosphonates | 1 | 2015 | 43 | 0.480 |
Why?
|
| Femur | 1 | 2015 | 75 | 0.470 |
Why?
|
| Cytotoxicity, Immunologic | 4 | 2023 | 276 | 0.470 |
Why?
|
| Ambulatory Care | 1 | 2018 | 414 | 0.470 |
Why?
|
| Health Care Costs | 1 | 2018 | 408 | 0.470 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2017 | 806 | 0.460 |
Why?
|
| Antigens, Neoplasm | 1 | 2017 | 408 | 0.440 |
Why?
|
| Child, Preschool | 19 | 2025 | 14884 | 0.430 |
Why?
|
| Humans | 48 | 2025 | 134152 | 0.420 |
Why?
|
| Antibodies, Monoclonal | 2 | 2017 | 1072 | 0.410 |
Why?
|
| Cancer Vaccines | 1 | 2014 | 190 | 0.390 |
Why?
|
| Lymphocyte Activation | 5 | 2020 | 724 | 0.390 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 1356 | 0.380 |
Why?
|
| Adolescent | 19 | 2025 | 20624 | 0.370 |
Why?
|
| Hematologic Neoplasms | 2 | 2025 | 294 | 0.330 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2024 | 1012 | 0.330 |
Why?
|
| Male | 24 | 2025 | 66125 | 0.300 |
Why?
|
| Mice | 11 | 2024 | 19055 | 0.300 |
Why?
|
| Incidence | 4 | 2024 | 3416 | 0.290 |
Why?
|
| Female | 22 | 2025 | 71926 | 0.260 |
Why?
|
| Animals | 12 | 2024 | 36557 | 0.250 |
Why?
|
| Infant | 13 | 2025 | 13240 | 0.250 |
Why?
|
| Mice, Inbred NOD | 4 | 2020 | 318 | 0.250 |
Why?
|
| Survival Rate | 4 | 2024 | 2218 | 0.240 |
Why?
|
| Liver Transplantation | 6 | 2020 | 1128 | 0.240 |
Why?
|
| Neutropenia | 3 | 2024 | 205 | 0.240 |
Why?
|
| Mice, SCID | 4 | 2020 | 615 | 0.230 |
Why?
|
| Young Adult | 8 | 2024 | 9944 | 0.220 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2024 | 23 | 0.220 |
Why?
|
| Mutagenesis, Insertional | 1 | 2025 | 157 | 0.220 |
Why?
|
| Adenosine Deaminase | 1 | 2024 | 89 | 0.220 |
Why?
|
| Prognosis | 8 | 2025 | 5086 | 0.210 |
Why?
|
| Mutagenesis | 1 | 2025 | 357 | 0.210 |
Why?
|
| Vincristine | 2 | 2024 | 196 | 0.210 |
Why?
|
| SEER Program | 2 | 2022 | 224 | 0.210 |
Why?
|
| Cell Proliferation | 4 | 2020 | 2563 | 0.200 |
Why?
|
| Sequence Deletion | 1 | 2025 | 539 | 0.200 |
Why?
|
| Interleukin-6 | 1 | 2024 | 451 | 0.190 |
Why?
|
| RNA, Long Noncoding | 1 | 2025 | 250 | 0.190 |
Why?
|
| Lymphocyte Depletion | 2 | 2024 | 125 | 0.190 |
Why?
|
| Treatment Outcome | 9 | 2025 | 13074 | 0.190 |
Why?
|
| Yttrium Radioisotopes | 1 | 2021 | 19 | 0.190 |
Why?
|
| Cohort Studies | 2 | 2024 | 5222 | 0.180 |
Why?
|
| Cytokines | 3 | 2017 | 1401 | 0.180 |
Why?
|
| Tumor Cells, Cultured | 2 | 2020 | 1107 | 0.180 |
Why?
|
| Polymerase Chain Reaction | 1 | 2025 | 1627 | 0.180 |
Why?
|
| Leukemia | 1 | 2024 | 379 | 0.170 |
Why?
|
| Lymphoma | 1 | 2024 | 336 | 0.170 |
Why?
|
| Vidarabine | 1 | 2020 | 78 | 0.170 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 1157 | 0.170 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2020 | 26 | 0.170 |
Why?
|
| United States | 4 | 2024 | 11763 | 0.170 |
Why?
|
| Induction Chemotherapy | 1 | 2020 | 57 | 0.160 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2020 | 94 | 0.160 |
Why?
|
| Aicardi Syndrome | 1 | 2019 | 15 | 0.160 |
Why?
|
| Automobiles | 1 | 2019 | 3 | 0.160 |
Why?
|
| Immunity | 1 | 2020 | 187 | 0.160 |
Why?
|
| Agenesis of Corpus Callosum | 1 | 2019 | 44 | 0.160 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2020 | 111 | 0.160 |
Why?
|
| Middle Aged | 4 | 2024 | 29397 | 0.160 |
Why?
|
| Embolization, Therapeutic | 1 | 2021 | 225 | 0.150 |
Why?
|
| Vocal Cord Paralysis | 1 | 2020 | 69 | 0.150 |
Why?
|
| Febrile Neutropenia | 1 | 2018 | 15 | 0.150 |
Why?
|
| Transplantation Conditioning | 2 | 2017 | 300 | 0.150 |
Why?
|
| Macrophages | 2 | 2014 | 711 | 0.150 |
Why?
|
| Cyclophosphamide | 1 | 2020 | 426 | 0.150 |
Why?
|
| Proportional Hazards Models | 1 | 2022 | 1488 | 0.140 |
Why?
|
| Bile Ducts, Extrahepatic | 1 | 2018 | 19 | 0.140 |
Why?
|
| Survival Analysis | 2 | 2018 | 1599 | 0.140 |
Why?
|
| Follow-Up Studies | 6 | 2025 | 5477 | 0.140 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 324 | 0.140 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2018 | 105 | 0.140 |
Why?
|
| Registries | 1 | 2024 | 1578 | 0.140 |
Why?
|
| Lymphocyte Count | 1 | 2017 | 125 | 0.130 |
Why?
|
| Bacterial Infections | 1 | 2020 | 329 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2017 | 152 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2017 | 145 | 0.130 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2017 | 43 | 0.130 |
Why?
|
| History, 20th Century | 1 | 2018 | 396 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2017 | 63 | 0.130 |
Why?
|
| Retrospective Studies | 10 | 2025 | 17540 | 0.130 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 1310 | 0.130 |
Why?
|
| Myeloid Cells | 1 | 2017 | 123 | 0.130 |
Why?
|
| L-Selectin | 1 | 2016 | 22 | 0.130 |
Why?
|
| Acetylation | 1 | 2017 | 195 | 0.130 |
Why?
|
| Bile Duct Neoplasms | 1 | 2018 | 121 | 0.130 |
Why?
|
| Cholangiocarcinoma | 1 | 2018 | 121 | 0.130 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2018 | 225 | 0.130 |
Why?
|
| Transduction, Genetic | 2 | 2014 | 296 | 0.130 |
Why?
|
| Adult | 6 | 2024 | 31943 | 0.120 |
Why?
|
| Infant, Newborn | 4 | 2024 | 8623 | 0.120 |
Why?
|
| Apoptosis | 2 | 2020 | 1946 | 0.120 |
Why?
|
| Neoplasms, Second Primary | 1 | 2017 | 166 | 0.120 |
Why?
|
| Cell Polarity | 1 | 2016 | 127 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 825 | 0.120 |
Why?
|
| Translocation, Genetic | 1 | 2017 | 363 | 0.120 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2016 | 97 | 0.120 |
Why?
|
| Antigens, CD19 | 1 | 2016 | 181 | 0.120 |
Why?
|
| Antineoplastic Agents | 1 | 2025 | 1853 | 0.120 |
Why?
|
| Liver Diseases | 1 | 2019 | 392 | 0.110 |
Why?
|
| Brain Diseases | 1 | 2018 | 310 | 0.110 |
Why?
|
| 4-1BB Ligand | 1 | 2014 | 11 | 0.110 |
Why?
|
| Antigens, CD1d | 1 | 2014 | 21 | 0.110 |
Why?
|
| Neoplasm Proteins | 1 | 2019 | 719 | 0.110 |
Why?
|
| Disease Management | 1 | 2018 | 567 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 407 | 0.110 |
Why?
|
| Genes, T-Cell Receptor | 1 | 2013 | 2 | 0.110 |
Why?
|
| Retroviridae | 1 | 2014 | 198 | 0.110 |
Why?
|
| Abnormalities, Multiple | 1 | 2019 | 979 | 0.110 |
Why?
|
| Sarcoma | 1 | 2016 | 209 | 0.100 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2016 | 521 | 0.100 |
Why?
|
| Health Personnel | 1 | 2018 | 541 | 0.100 |
Why?
|
| Radiography | 1 | 2015 | 826 | 0.100 |
Why?
|
| Liver | 2 | 2019 | 1879 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2018 | 700 | 0.100 |
Why?
|
| Adoptive Transfer | 1 | 2013 | 241 | 0.100 |
Why?
|
| Heart Defects, Congenital | 1 | 2024 | 1884 | 0.100 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 787 | 0.100 |
Why?
|
| Health Status | 1 | 2014 | 412 | 0.100 |
Why?
|
| Cardiovascular Diseases | 1 | 2025 | 2090 | 0.090 |
Why?
|
| Cell Line, Tumor | 4 | 2024 | 3798 | 0.090 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2017 | 567 | 0.090 |
Why?
|
| Risk | 1 | 2013 | 837 | 0.090 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 746 | 0.090 |
Why?
|
| Parents | 1 | 2018 | 1071 | 0.090 |
Why?
|
| Hepatectomy | 2 | 2023 | 124 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2024 | 1317 | 0.090 |
Why?
|
| Thrombocytopenia | 2 | 2024 | 237 | 0.080 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 1391 | 0.080 |
Why?
|
| Postoperative Complications | 2 | 2021 | 3178 | 0.080 |
Why?
|
| Graft vs Host Disease | 1 | 2014 | 619 | 0.080 |
Why?
|
| Pediatrics | 1 | 2018 | 1215 | 0.080 |
Why?
|
| Cell Line | 1 | 2014 | 2864 | 0.080 |
Why?
|
| Aged | 2 | 2024 | 21773 | 0.080 |
Why?
|
| Mutation | 2 | 2022 | 6336 | 0.080 |
Why?
|
| Phenotype | 1 | 2017 | 4598 | 0.070 |
Why?
|
| Fatal Outcome | 2 | 2018 | 378 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 2578 | 0.060 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2025 | 67 | 0.060 |
Why?
|
| Ribonuclease III | 1 | 2025 | 103 | 0.060 |
Why?
|
| Inosine | 1 | 2024 | 12 | 0.060 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2025 | 150 | 0.050 |
Why?
|
| Hydroxamic Acids | 1 | 2024 | 65 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2025 | 2137 | 0.050 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2024 | 92 | 0.050 |
Why?
|
| Margins of Excision | 1 | 2023 | 59 | 0.050 |
Why?
|
| Kynurenine | 1 | 2023 | 26 | 0.050 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2023 | 22 | 0.050 |
Why?
|
| Herpesvirus 4, Human | 1 | 2025 | 675 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2023 | 129 | 0.050 |
Why?
|
| Consensus | 1 | 2025 | 732 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 358 | 0.040 |
Why?
|
| Hoarseness | 1 | 2020 | 13 | 0.040 |
Why?
|
| Tacrolimus | 1 | 2020 | 108 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 1 | 2023 | 352 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 377 | 0.040 |
Why?
|
| Prednisone | 1 | 2020 | 289 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2020 | 225 | 0.040 |
Why?
|
| Respiratory Sounds | 1 | 2020 | 72 | 0.040 |
Why?
|
| Recurrence | 1 | 2023 | 1472 | 0.040 |
Why?
|
| Corpus Callosum | 1 | 2019 | 104 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 698 | 0.040 |
Why?
|
| Chromosome Aberrations | 1 | 2022 | 628 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2025 | 2915 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 203 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2025 | 951 | 0.040 |
Why?
|
| Chromosome Banding | 1 | 2017 | 140 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 825 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2017 | 344 | 0.030 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2017 | 128 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 703 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2017 | 336 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 1493 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 1 | 2016 | 133 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 675 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2016 | 401 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 1146 | 0.030 |
Why?
|
| Surgical Procedures, Operative | 1 | 2016 | 191 | 0.030 |
Why?
|
| Disease Progression | 1 | 2020 | 2266 | 0.030 |
Why?
|
| Biopsy | 1 | 2017 | 1304 | 0.030 |
Why?
|
| Cell Survival | 1 | 2016 | 890 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2024 | 1787 | 0.030 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 820 | 0.030 |
Why?
|
| Chemokine CCL20 | 1 | 2012 | 16 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2012 | 61 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2012 | 103 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 276 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2012 | 399 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 920 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2016 | 3188 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 703 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2020 | 6601 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2017 | 1187 | 0.020 |
Why?
|
| Genomics | 1 | 2016 | 1681 | 0.020 |
Why?
|
| Cell Movement | 1 | 2012 | 920 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2016 | 4016 | 0.020 |
Why?
|
| Texas | 1 | 2014 | 3716 | 0.020 |
Why?
|
| Risk Factors | 1 | 2019 | 11181 | 0.010 |
Why?
|